Presbyopia

Published data from a pair of Phase 3 clinical trials demonstrated a reversal of pharmacologically-induced mydriasis with a favorable safety profile, according. to the company.

Top-line data from the trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia are expected in 2025.

LNZ100 is an aceclidine-based ophthalmic solution and demonstrated statistically significant results in the Phase 3 CLARITY study.

How to personalize multifocal contact lens recommendations for your patients.

Results from the THRIVE study found that when reading glasses were given to first-time wearers, monthly median incomes increased by 33%.

The company selected LNZ100, designed to treat presbyopia, as its lead candidate and expects to submit an NDA in mid-2024.

Hear how this daily disposable silicone hydrogel option fits patients' busy and active lifestyles.

Even if DLS is completely normal and expected, it can be mentally and emotionally difficult for patients.

Here’s why formulation matters.

Qlosi (Orasis Pharmaceuticals) approved to treat presbyopia.

Innovations in multifocal contact lenses have expanded options.

Post-hoc data helps shine light on better understanding what patient demographics are best suited for presbyopia drops.

The TOTAL30 multifocal contact lens helps address the needs of visual and comfort for patients with presbyopia.

Research presented at the American Academy of Optometry 2023 meeting illustrates success in fitting presbyopia patients in soft multifocal contact lenses.

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF, a topical, fixed-dose combination for the treatment of presbyopia, have recently been released.

Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.

Making the most of multifocal contact lenses in your practice.

Doctors should consider a few key points before writing a prescription.

Managing patient expectations is key to selecting the best lens

Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.

Preeya Gupta, MD, reported results of the trials at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, showed that CSF-1, a low dose pilocarpine with an optimized formulation, demonstrated significant 2-line improvement from baseline.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

A look back on what happened in optometry during the week of March 20-March 24.

Following the enrollment completion for Brimochol PF, topline Phase 3 data for the presbyopia candidate is expected in Q2 2023.

A look back on what's happened in optometry during the week of February 25-March 2.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

A look back on what's happened in optometry during the week of February 18-February 23.

A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.